-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Lowers Price Target to $90

Benzinga·01/02/2026 11:05:24
Listen to the news
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and lowers the price target from $145 to $90.